These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 9371648

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.
    Ethelberg S, Lovmand J, Schmidt J, Luz A, Pedersen FS.
    J Virol; 1997 Oct; 71(10):7273-80. PubMed ID: 9311802
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site.
    Ethelberg S, Hallberg B, Lovmand J, Schmidt J, Luz A, Grundström T, Pedersen FS.
    J Virol; 1997 Feb; 71(2):1196-206. PubMed ID: 8995642
    [Abstract] [Full Text] [Related]

  • 7. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.
    Ethelberg S, Tzschaschel BD, Luz A, Diaz-Cano SJ, Pedersen FS, Schmidt J.
    J Virol; 1999 Dec; 73(12):10406-15. PubMed ID: 10559359
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus.
    Morrison HL, Soni B, Lenz J.
    J Virol; 1995 Jan; 69(1):446-55. PubMed ID: 7983741
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus.
    Hallberg B, Schmidt J, Luz A, Pedersen FS, Grundström T.
    J Virol; 1991 Aug; 65(8):4177-81. PubMed ID: 1649324
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Contributions to transcriptional activity and to viral leukemogenicity made by sequences within and downstream of the MCF13 murine leukemia virus enhancer.
    Tupper JC, Chen H, Hays EF, Bristol GC, Yoshimura FK.
    J Virol; 1992 Dec; 66(12):7080-8. PubMed ID: 1331510
    [Abstract] [Full Text] [Related]

  • 20. CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes.
    Zaiman AL, Nieves A, Lenz J.
    J Virol; 1998 Apr; 72(4):3129-37. PubMed ID: 9525638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.